Basic information Safety Supplier Related

CONIVAPTAN

Basic information Safety Supplier Related

CONIVAPTAN Basic information

Product Name:
CONIVAPTAN
Synonyms:
  • CONIVAPTAN
  • N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-[1,1'-biphenyl]-2-carboxamide
  • N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
  • ZINC 12503187
  • [1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-
  • Kaunivartan
CAS:
210101-16-9
MF:
C32H26N4O2
MW:
498.583
Product Categories:
  • API
Mol File:
210101-16-9.mol
More
Less

CONIVAPTAN Usage And Synthesis

Description

Conivaptan, a vasopressin antagonist, was discovered and developed by Yamanouchi for the treatment of hyponatraeum associated with congestive heart failure.

Uses

2-Methyl-1,4,5,6-tetrahydrobenzo[b]imidazo[4,5-d]azepine is an impurity of Conivaptan(C384700). Conivaptan is used in the treatment of congestive heart failures.

Definition

ChEBI: The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of argini e vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).

Synthesis

After looking at several different approaches to the synthesis, a convergent approach, shown in the Scheme 4, was developed for large scale synthesis. Bromination of benzazepinone 10 with pyridinium hydrobromide perbromide in chloroform followed by recrystallization gave bromide 11. Reaction of bromide 11 with ethaneimidate hydrochloride in the presence of potassium carbonate in toluene or chloroform gave the desired imidazole 12 in 69% yield. Although chlo-roform provided a slightly better yield, for large scale preparation, toluene was used to minimize halogenated solvent waste and because the quality of product was similar or better than with use of chloroform. Deprotection of the tosylate was found to be effective with heating the sulfonamide 12 in 80% sulfuric acid at 80oC. The benzazepinone product 13 was obtained in 90% yield after crystallization from acetonitrile and water mixture.
Synthesis of the coupling partner 16 required to provide conivaptan was synthesized in 95% yield from biphenyl 2- benzoic acid via sequential reaction with thionyl chloride in toluene followed by coupling with aminobenzoic acid in acetone with N,N-dimethylaniline as a base. High quality acid 16 was obtained by crystallization from DMF and water. The acid 16 was activated by converting it into acid chloride with thionyl chloride in acenonitrile, to which was added imidazo benzazepine 13 in toluene and, after recrystallization in acidic ethanol, gave conivaptan hydrochloride (III) in 90% yield.

CONIVAPTANSupplier

LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185 18149758185
Email
sales-cpd@caerulumpharma.com
Taizhou Tongxin Bio-Tech Co., Ltd
Tel
0523-18601685-898 18652728585
Email
sales@allyrise.com
Shanghai Synchem Pharma Co., ltd
Tel
21-619849051-1 18521059765
Email
synchempharma@aliyun.com
More
Less

CONIVAPTAN(210101-16-9)Related Product Information